FDA Presentation to the Oncologic Drugs Advisory Committee

9/25/01


Click here to start


Table of Contents

FDA Presentation to the Oncologic Drugs Advisory Committee

Review Committee

Characteristics of 2B8

Ibritumomab tiuxetan Structure

Zevalin? Kit Components

Preparation of Radiolabeled-Zevalin?

Zevalin? Therapy Components

Proposed Indication

Author: Shapirom